CYD19 impairs EMT-associated tumor invasion and metastasis by reversing SNAI1-driven EMT; this finding provides evidence that pharmacologic interference with SNAI1 acetylation may exert potent therapeutic effects in patients with cancer. Here, SNAI1 is linked to cancer.